AJP - Endo Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 297: E568-E577, 2009. First published June 2, 2009; doi:10.1152/ajpendo.00297.2009
0193-1849/09 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
297/3/E568    most recent
00297.2009v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Potenza, M. A.
Right arrow Articles by Montagnani, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Potenza, M. A.
Right arrow Articles by Montagnani, M.

REVIEWS

Vascular actions of insulin with implications for endothelial dysfunction

Maria Assunta Potenza, Francesco Addabbo, and Monica Montagnani

Department of Pharmacology and Human Physiology, Medical School, University of Bari, Bari, Italy

Submitted 8 May 2009 ; accepted in final form 31 May 2009

ABSTRACT

Hemodynamic actions of insulin depend largely on the hormone's ability to stimulate synthesis and release of endothelial mediators, whose balanced activity ensures dynamic control of vascular function. Nitric oxide (NO), endothelin-1 (ET-1), and reactive oxygen species (ROS) are important examples of endothelial mediators with opposing properties on vascular tone, hemostatic processes, and vascular permeability. Reduced NO bioavailability, resulting from either insufficient production or increased degradation of NO, characterizes endothelial dysfunction. In turn, endothelial dysfunction predicts vascular complications of metabolic and hemodynamic disorders. In the cardiovascular system, insulin stimulates the production and release of NO, ET-1, and ROS via activation of distinct intracellular signaling pathways. Under insulin-resistant conditions, increased insulin concentrations and/or impaired insulin-signaling pathways in the vasculature may contribute to imbalance in secretion of endothelial mediators that promote pathogenesis of vascular abnormalities. This short review describes signaling pathways involved in insulin-stimulated release of NO, ROS, and ET-1 and suggests possible molecular mechanisms by which abnormal insulin signaling may contribute to endothelial dysfunction.

insulin signaling; insulin resistance; reactive oxygen species; endothelin-1; nitric oxide



Address for reprint requests and other correspondence: M. Montagnani, Dept. of Pharmacology and Human Physiology, Medical School, Univ. of Bari, Policlinico - P.zza G. Cesare, 1, 70124 Bari, Italy (e-mail: monica{at}farmacol.uniba.it)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2009 by the American Physiological Society.